Q1 2025 13F Holders as of 3/31/2025
-
Type / Class
-
Equity / Common Stock, $0.0001 par value
-
Shares outstanding
-
700K
-
Number of holders
-
15
-
Total 13F shares, excl. options
-
2.13M
-
Shares change
-
+2.12M
-
Total reported value, excl. options
-
$1.05M
-
Value change
-
+$1.05M
-
Number of buys
-
15
-
Price
-
$0.50
Significant Holders of TRANSCODE THERAPEUTICS, INC. - Common Stock, $0.0001 par value (RNAZ) as of Q1 2025
15 filings reported holding RNAZ - TRANSCODE THERAPEUTICS, INC. - Common Stock, $0.0001 par value as of Q1 2025.
TRANSCODE THERAPEUTICS, INC. - Common Stock, $0.0001 par value (RNAZ) has 15 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 2.13M shares
.
Largest 10 shareholders include Anson Funds Management LP (1.46M shares), UBS Group AG (264K shares), SABBY MANAGEMENT, LLC (229K shares), Warberg Asset Management LLC (50K shares), CORSAIR CAPITAL MANAGEMENT, L.P. (40K shares), ACADIAN ASSET MANAGEMENT LLC (22.3K shares), COMMONWEALTH EQUITY SERVICES, LLC (21.7K shares), SouthState Corp (18K shares), Ground Swell Capital, LLC (14.4K shares), and MORGAN STANLEY (5K shares).
This table shows the top 15 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.